What is Microvisk?
Microvisk Technologies, founded in 2004 and based in Oxford, UK, is dedicated to enhancing patient care through the design and development of cutting-edge medical devices for anticoagulation monitoring. The company leverages patented Micro Electro Mechanical Sensors (MEMS) technology to create its flagship CoagMax PT/INR System, which facilitates accurate and user-friendly at-home and point-of-care testing. Microvisk's solutions are crucial for individuals undergoing anticoagulant therapy and for healthcare providers seeking efficient monitoring methods. The company operates under ISO 13485:2016 accreditation, highlighting its commitment to quality and regulatory compliance in the medical device sector.
How much funding has Microvisk raised?
Microvisk has raised a total of $22.9M across 3 funding rounds:
Series A
$3.9M
Series C
$9.5M
Series B
$9.5M
Series A (2010): $3.9M with participation from Oxford Technology Management and Finance Wales
Series C (2011): $9.5M, investors not publicly disclosed
Series B (2011): $9.5M supported by New Hill Management and Oxford Technology
Key Investors in Microvisk
Oxford Technology Management
Oxford Technology Management manages SEIS and EIS funds focused on high-growth technology startups, particularly in the Oxford region, aiming for significant capital growth through strategic investments in early-stage companies.
Finance Wales
Finance Wales, now part of the Development Bank of Wales, provides business finance solutions including loans and equity for companies in Wales, with a focus on technology ventures and economic growth.
New Hill Management
New Hill Management is an investment entity that has participated in Microvisk's funding rounds, indicating a strategic interest in the medical device sector.
What's next for Microvisk?
With the recent major strategic investment, Microvisk is poised for accelerated growth and market expansion. The company's focus on improving the accuracy and accessibility of PT/INR testing aligns with the increasing demand for remote patient monitoring and efficient point-of-care diagnostics. This backing will likely fuel further research and development, enhance manufacturing capabilities, and support broader commercialization efforts, solidifying Microvisk's position in the competitive medical device landscape. The company's trajectory suggests a move towards scaling operations and potentially exploring new therapeutic areas or advanced features for its monitoring systems.
See full Microvisk company page
